Orexigen (OREX) Higher Early Heading into Qnexa's PDUFA Date (VVUS)

Orexigen Therapeutics (Nasdaq: OREX) is up in early trading today following a note from Jefferies on the potential for Orexigen rival VIVUS' (Nasdaq: VVUS) obesity drug, Qnexa. The firm gives a 50-50 chance of FDA approval for Qnexa. For more on the note, click here.

Volatility on the session is up about 1 percent, with shares moving above 4 percent on the session.

VIVUS has a PDUFA date of July 17th for Qnexa

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Hunterbrook Capital is short bonds issued by Sammons Financial Group and short Guggenheim Strategic Opportunities Fund
• IREN Limited (IREN) call put ratio 3.4 calls to 1 put into quarter results
• Synopsys (SNPS) call put ratio 2.1 calls to 1 put into quarter results